Last week IPO filed an amicus brief in the U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc. IPO argued that isolated human DNA is patent-eligible subject matter. IPO said a ban on patenting isolated human DNA would negatively impact research, technology and innovation, and be contrary to the constitutional mandate for the Patent Act to “promote the progress of . . . the useful arts.” The case will be argued on April 15. The IPO brief was approved by the Board of Directors and drafted by IPO members PAUL BERGHOFF, KEVIN NOONAN, and JEFFREY ARMSTRONG of the McDonnell, Bohen, Hulbert and Berghoff firm. IPO President RICHARD PHILLIPS and IPO Amicus Brief Committee Chair KEVIN RHODES were on the brief.